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INTRODUCTION 
Compliance with anti-infective drugs is possibly the 
most important issue that will face communicable 
disease physicians in the new millennium. Non- 
compliance is common among patients prescribed 
self-administered medication and carries heavy costs 
for the individual, the health provider and public 
health. For the individual, non-compliance may result 
in a reduction of therapeutic benefit, drug resistance, 
drug toxicity and the greater likelihood of disease 
progression. For the health provider the cost is 
enormous in terms of wasted drugs and the cost of 
treating additional morbidity. It has been estimated 
that hospitabzation due to non-compliance accounts 
for 11.7% of all healthcare expenditure in the USA 
[ 11. Moreover, with communicable diseases there are 
important public-health implications, including failure 
to eliminate the infection, increased drug resistance in 
the community and prolonged infectivity. 
WHAT IS COMPLIANCE? 
Compliance can be defined as the extent to which 
a person’s behavior (in terms of taking medications, 
following diets or executing lifestyle changes) coincides 
with medical or health advice. It is most widely used 
to describe the degree to w h c h  patients follow the 
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regimen of medicine-taking recommended by their 
doctor and therefore has attributes ofboth quantity and 
time. The term compliance has been criticized on the 
ground. that it disregards the autonomy of the patient. 
‘Adher’mce’, which connotes patient choice in follow- 
ing the prescribed regimen, is often used in preference. 
In this article, the terms compliance and adherence will 
be used interchangeably. 
Types of non-compliance 
Compliance is not a simple matter of obeying 
instructions. Non-compliance exists on different levels 
and is expressed in different ways. Non-compliance 
may be intentional, based on reasoned decision-making 
influenced by the patient’s views on drugs and his or 
her own condition [2], or it may be unintentional, 
arising from factors such as depression, lack of coping, 
disorganized lifestyle, communication problems and 
lack of information. The most commonly observed 
forms of non-compliance are: (1) failure to have the 
prescription dispensed, (2) omission of doses, (3) errors 
of dosage, (4) deviations in dose timing and (5) early 
cessatiom of the drug [3]. An essential factor in 
evaluating compliance for different treatments is the 
threshold of therapy needed to maintain the effective- 
ness of the regimen (i.e. how much compliance is 
enough). For example, triple combination annretroviral 
therapy for HIV infection necessitates a high degree of 
compliance to suppress viral replication. In contrast, 
high-dosage oral contraceptives can maintain contra- 
ceptive efficacy even with lapses in dosing of several 
days. 
METHODS FOR MEASURING COMPLIANCE 
Patient !self-reports 
Historytaking, diaries, questionnaires and self-report 
scales have all been used to obtain patient reports of 
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compliance. These patient self-reports have been shown 
to greatly overestimate adherence [4]. 
Pill counts 
In this method the pill bottle is recovered at the end of 
a course of medicine and the number of remaining pills 
counted to measure drug underuse or overuse. This 
technique tends to overestimate adherence, and similar 
pill count results may be obtained from very different 
types of non-compliance. Patients often fail to bring 
their medication with them a t  the time of their clinic 
visit or may empty their pdl bottles rather than adnut  
non-coniphance. While far from satisfactory, pfi  counts 
continue to be almost universally used in drug trials [5]. 
Pharmacologic markers 
This method involves the addition of a low-dose 
pharmacologic marker to the medication under study. 
A measure of adherence is obtained by measuring 
the level of the pharmacologic indicator in the blood 
or in urine. Low-dose phenobarbitone has been widely 
used as an indicator [6]. This method of measuring 
adherence has been shown to be both accurate and 
reproducible. 
Monitoring of the primary therapeutic agent 
In this method, adherence is assessed by measuring 
the plasma or urine concentration of the primary 
therapeutic agent. It is highly dependent on pharma- 
cokinetics, and drugs with short half-lives, such as 
penicillin, are unsuitable for this method. Biochenlical 
validation is not feasible with many compounds for 
which assays are not readily available. The results of 
blood and urine tests are influenced by variable drug 
absorption, rnetabolisni and clearance. This method 
is problematic, because the levels taken a t  the time 
of measurement give no indication of blood levels 
between measurements, especially for short-acting 
drugs. 
Electronic monitoring 
Electronic monitoring devices have been developed 
to measure adherence to medication. These devices 
record the times and dates when the medication bottle 
has been opened and are unique in being able to 
reveal accurately the temporal patterns of dosing. The 
u5e of this method has revealed drug holidays (multiday 
lapses in dosing) and ‘white-coat compliance’ 171 (the 
tendency for usually poor compliance to improve in the 
day or two prior to a scheduled visit to the physician) 
to be common. In interpretation of the data, it is 
assumed that medication removed from its container 
is actually ingested. Although this may not be true, 
it would require persistent adherence to the dosing 
schedule for a patient to fake good compliance, as the 
micro-circuit records the time of each opening. 
Electronic monitoring devices exist for medication 
presented as loose tablets, capsules, tablets or capsules 
in blister packs, inhaled medication and eye drops. 
Electronic monitoring and pharmacologic markers 
are complementary methods, as together they enable 
accurate measurement to be made of dose taking and 
dose timing. 
FREQUENCY OF NON-COMPLIANCE 
While there is a consensus that non-compliance is an 
important problem, different approaches to measure- 
ment, to the definition of non-compliance and to 
endpoint assessments mean that estimates of the size of 
the problem vary widely. Estimates of poor compliance 
range from 20% to 80% [ 8 ] .  A review of method- 
ologically rigorous studies concluded that compliance 
with different long-term melcation regimens tended 
to converge to approximately 50%> [9]. 
FACTORS AFFECTING COMPLIANCE 
Factors relating to the drug regimen 
The complexity of the treatment regimen has a sign- 
ficant impact on compliance [ 101. Reliable measures 
indicate little ddrerence in compliance between once- 
and twice-daily regimens, but considerably higher rates 
of omitted doses and errors in dose timing with three 
times a day or four times a day dosing [ 11,121. Long- 
acting drugs, or drugs that can be administered 
once daily, can be important in helping to achieve 
compliance. However, once-daily dosing has a major 
problem. Unless the once-daily dose has a long plasma 
half-life, if there is a missed dose it will result in a low 
serum drug concentration for an 18-24-h period. 
Continuity of therapeutic action is best ensured when 
the prescribed interval between doses is substantially 
shorter than the duration of the drug action. The 
number of drugs taken concurrently also affects 
compliance [13]. Some studies suggest that frequency 
of dosing is a more important determinant of com- 
pliance than the number of different drugs prescribed 
[ 14,151. 
There IS evidence that the level of non-compliance 
rises as the duration oftherapy increases 1161. In a study 
of patients with otitis media given a 10-day course 
of oral penicillin, up to 50% were found to be non- 
compliant by day 3. rising to 70% by days 6-7 [ 171. 
Unpleasant side effects can affect compliance. In an 
early study of paminosalicylic acid for tuberculosis 
1181, in which a third of patients experienced nausea 
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and diarrhea, less than 50% of patients complied with 
their regimen. In patients with HIV infection, side 
effects, including leukopenia, anemia and gastro- 
intestinal upset, have been shown to lead to decreased 
adherence and treatment cessation [19]. 
Patient-related factors 
Factors such as age, gender, educational level, socio- 
economic status and personality traits have been shown 
to influence compliance. However, the factors most 
strongly associated with improved compliance are 
patients’ health beliefs, social support, patient under- 
standing of the prescribed therapy and the doctor- 
patient relationship. These are clearly connected by the 
central roles of communication and reinforcement. 
Patients’ beliefs about illness and mechcation are 
strong determinants of seeking care and accepting 
therapy. Compliance is strongly influenced by the 
patient’s perception that their wellbeing is at  threat &om 
the disease and that the benefits from prescribed 
therapy outweigh perceived barriers to compliance 
with it (e.g., drug cost, side effects and complexity of 
the regmen). Lay beliefs about illness and medication 
may differ quite markedly bom those held by health 
professionals. ‘This leads to difficulties in communi- 
cation, which can result in confusion, frustration and 
non-compliance [20]. This may be particularly true 
where the patient and provider have different cultural 
or ethnic backgrounds. Frequently, medicine is aimed 
at the dnease process and not at the immediate 
alleviation of symptoms. This differentiation between 
symptoms and disease process is not widely understood 
by patients, and leads to non-compliance and early 
cessation of treatment, particularly with antibiotics. A 
Europe-wide study of patients’ attitudes to the use of 
antibiotics for respiratory tract infection showed that 
81% of respondents expected symptoms to improve 
after 3 days’ treatment; for 87%, feeling better justified 
stopping the course of antibiotics [17]. This study 
revealed differences between countries in how anti- 
biotics were perceived. Respondents &om Belgium, 
Turkey and Italy showed particular concern that anti- 
biotics could undermine natural immunity, particularly 
in chddren. Side effects, addiction, dependency and the 
development of resistance were also cited as concerns. 
Major causes of poor compliance include the 
failure to understand the importance of the drug 
therapy and the potential consequences of not using the 
medication according to instructions, and the failure 
to understand the instructions given. A good under- 
standing of the prescribed therapy and knowledge 
about the reasons for tahng the drug and the 
complexity of the regimen have been shown to 
improve adherence significantly with anti-HIV drugs 
[21,22]. Clear explanation of the timing of doses is 
needed. A study to assess the relationship between the 
prescriber’s instructions and the patient’s adherence to 
a prescribed 5-day antibiotic schedule showed that 
99.6% of patients took the correct number of doses 
but only 32.6% took their medication within 1 h 
before or after the optimal 12-hour interval [23). In 
another study of how patients interpret prescription 
instructions, 36% of patients interpreted ‘tetracycline, 
250 m g  every 6 h’ to mean every 6 h around the clock 
for a total of four doses each day About 25% of the 
patients divided the time they were awake and took 
only three doses throughout the 24-h period [24]. 
Written instructions which are clearly explained 
by a doctor, pharmacist or nurse can improve com- 
pliance. Aids such as timed pill dspensers, alarm clocks, 
multicompartment containers and dose checklists for 
comp1e.x regimens have also been shown to be effective. 
Perhap:s more fundamental is the need for health 
professionals to use their verbal communication skills 
and knowledge to tailor the treatment plan as much as 
possible to the patient’s lifestyle and circumstances. The 
health ]professional and patient must work together to 
identifi routines so that medication is administered at 
times that correspond to some of the patient’s regular 
activitirs. Various aspects of the relationship between 
patients and health professionals have been identified 
as being important to compliance (these include con- 
tinuity of care, shared beliefs regarding illness and 
medication [20] and patient satisfaction with care 
provided [25]). Pharmacists, nurses and doctors have 
figured prominently in successful strategies to improve 
adheren’ce but there is very little research evaluating 
the comparative effectiveness of different healthcare 
professionals on compliance. 
COMPLlANCE AND CONCORDANCE 
Non-compliance is a phenomenon ‘so widespread that 
it mighi: well be considered normal behaviour’ [26]. 
As such, when explanations are sought for treatment 
failure, it must be considered alongside factors such as 
pharmacologic non-response and poor bioavailability. 
The lack of rigorous study design in compliance 
research makes evaluation of interventions to improve 
compliaince problematic. However, it would appear that 
two of the most important factors to ensure good 
compliance are clear instructions to the patient (Lnlung 
dosing to some regular feature of the patients’ daily 
routine) and the simplest regimen consistent with 
continuous efficacy. 
A recent Royal Pharmaceutical Society Working 
Party report from the UK [27] concluded that for 
patients to be enabled to take medicines to best 
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effect, it is necessary to rethink the patient/prescriber 
consultation. The concept of ‘concordance’ is mooted 
as an alternative to ‘compliance’. Concordance is based 
on the notion that the work of the prescriber and 
the patient is a negotiation between equals and that 
therefore the aim is a therapeutic alliance between 
them. How far this therapeutic alliance will be achieved 
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SELF-ASSESSMENT QUESTIONS 
Please ariswer true orfalse: 
1. Once-daily antibiotic medication gives greatly 
superior compliance to twice-daily medication. 
2. The most effective way of measuring compliance 
is to ask patients to bring in their pills, to count 
them and to compare them with the number which 
should have been taken. 
3 .  Pharmacologic markers provide the most accurate 
measure of the timing of dosing. 
4. Many of the problems of patients complying with, 
or adhering to, their therapy are due to the lack of 
understandmg that the doctors have of the patients’ 
particular situations and beliefs concerning the 
disease. One of the most important ways to improve 
compliance on long-term medication is to spend 
time in ensuring that patients understand the long- 
term benefits of their medication. 
5. If you have a good standard explanation of why 
drugs are important, you can give this either verbally 
or in writing to all your patients. 
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6 .  Patients who are not compliant are rare and can be 3.  False. Pharmacologic markers provide the most 
accurate measurement of dose taking. Electronic 
monitoring i s  the most appropriate method to 
easily recognized by health professionals. 
SELF-ASSESSMENT ANSWERS 
I .  False. There appears to be little difference in com- 
pliance between once-daily and twice-daily medica- 
tions. Unless the drug has a long plasma half-life, a 
missed dose of once-daily medication can lead to 
a low serum drug concentration for an extended 
period. 
3. False. Pill counting is one of the least effective 
methods of measuring compliance. It tends to over- 
estimate adherence, especially where patients dump 
their medication before their clinic visit. 
demonstrate dose timing. 
4. Trur:. This is one of the most important messages 
5. 
6. 
that arises fiom compliance research. 
False. Verbal and written explanations may need to 
be adapted for particular patients, e.g. those fbm 
dskrent cultural or ethnic backgrounds. 
False. Non-compliance is not a deviant behavior but 
a common phenomenon arising f b m  factors relating 
to the drug, the health provider, and the patient, and 
must be considered when seeking explanations for 
treatment failure. 
